ASH: Modified Regimen Slows Diffuse Large B-Cell Lymphoma

TUESDAY, Dec. 14, 2021 -- For patients with diffuse large B-cell lymphoma (DLBCL), a modification of the regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), in which vincristine is replaced with polatuzumab...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news